TABLE 2.
Distribution of TTV infection among HD patients
| Parameter | Unit 1 (n = 81)
|
Unit 2 (n = 69)
|
||
|---|---|---|---|---|
| TTV DNA+(n = 30 [37.0%]) | TTV DNA−(n = 51 [63.0%]) | TTV DNA+(n = 13 [18.8%]) | TTV DNA−(n = 56 [81.2%]) | |
| Mean ± SD age (yr) | 61.7 ± 15.4 | 59.7 ± 15.8 | 57.1 ± 15.2 | 64.8 ± 13.7 |
| Sex ratio (male/female) | 15/15 | 30/21 | 4/9 | 30/26 |
| Mean ± SD dialysis duration (mo) | 76.5 ± 79.6 | 85.3 ± 85.6 | 58.7 ± 52.9 | 63.3 ± 60.7 |
| No. of patients with transfusion and/or graft | 24 | 33 | 8 | 30 |
| No. (%) of patients from: | ||||
| Africa | 7 (58.3) | 5 (41.7) | 8 (34.8) | 15 (65.2) |
| South Europea | 4 (40.0) | 6 (60.0) | 2 (33.3) | 4 (66.7) |
| France/North Europe | 19 (32.2) | 40 (67.8) | 2 (5.3) | 36 (94.7) |
| No. (%) of patients in disease groupb: | ||||
| I | 8 (61.5) | 5 (38.5) | 3 (30.0) | 7 (70.0) |
| II | 6 (28.6) | 15 (71.4) | 1 (16.7) | 5 (83.3) |
| III | 3 (50.0) | 3 (50.0) | 1 (9.1) | 10 (90.9) |
| IV | 1 (25.0) | 3 (75.0) | 1 (100) | 0 |
| V | 4 (33.3) | 8 (66.7) | 2 (18.2) | 9 (81.8) |
| VI | 5 (38.5) | 8 (61.5) | 5 (29.4) | 12 (70.6) |
| VII | 3 (25.0) | 9 (75.0) | 0 | 13 (100) |
| No. of patients with viral marker type: | ||||
| Anti-HBcc | 13 (2) | 12 (4) | 4 (1) | 11 (1) |
| Anti-HCV | 5 | 11 | 4 | 14 |
| HCV RNA | 5 | 7 | 2 | 10 |
| GBV-C/HGV RNA | 8 | 10 | 0 | 2 |
a
Spain, Italy, and Greece.
b
As defined in Materials and Methods.
c
Values in parentheses represent the number of patients with positive HBs antigen.